"Disease" Definition Is Key Issue In Structure/Function Claims Rule - Henney
This article was originally published in The Tan Sheet
Executive Summary
The appropriateness of the new definition of "disease" included in FDA's April 1998 proposed rule on structure/function claims is a key issue emerging from the more than 100,000 comments received on the proposal, FDA Commissioner Jane Henney, MD, noted at a House Government Reform Committee hearing March 25. The hearing was called to review FDA's implementation of the Dietary Supplement Health & Education Act, and, in particular, the structure/function claims proposal.
You may also be interested in...
Disclaimers May Be "Subterfuge" For Disease Claims, PhRMA Exec Warns
FDA should be cautious in allowing a disclaimer statement that could mislead consumers into believing dietary supplements can cure or prevent disease, a PhRMA rep maintained at FDA's Aug. 4 public meeting on the regulation of supplement structure/ function claims in Washington, D.C.
Disclaimers May Be "Subterfuge" For Disease Claims, PhRMA Exec Warns
FDA should be cautious in allowing a disclaimer statement that could mislead consumers into believing dietary supplements can cure or prevent disease, a PhRMA rep maintained at FDA's Aug. 4 public meeting on the regulation of supplement structure/ function claims in Washington, D.C.
Disclaimers May Be "Subterfuge" For Disease Claims, PhRMA Exec Warns
FDA should be cautious in allowing a disclaimer statement that could mislead consumers into believing dietary supplements can cure or prevent disease, a PhRMA rep maintained at FDA's Aug. 4 public meeting on the regulation of supplement structure/ function claims in Washington, D.C.